CAMPATH (alemtuzumab)

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Hematologic MalignanciesNon-Hodgkin's Lymphoma

Phase 1

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

TerminatedNCT00077961

Genzyme, a Sanofi CompanyNon-Hodgkin's Lymphoma

Start: 2003-12-31Target: 49Updated: 2015-03-26

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

TerminatedNCT00113048

Genzyme, a Sanofi CompanyHematologic Malignancies

Start: 2003-12-31End: 2005-09-30Target: 24Updated: 2014-02-05